Pluristem is developing standardized cell therapies derived from the human placenta.
Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT) will include a going concern warning from its auditor in its upcoming annual financial report for 2009.
This will not be the first going concern warning by the drug development company; it has published them every year for the past three years, as well as in several of the preceding years. Despite the warnings, the company just keeps on going.
Pluristem is developing standardized cell therapies derived from the human placenta, a non-embryonic adult stem cell source. The company is undergoing Phase I clinical trial for its treatment for critical limb ischemia, an obstruction of the arteries that can lead to chronic wounds and gangrene.
Pluristem's share closed at $1.34 on Friday, giving a market cap of $21 million.
Published by Globes [online], Israel business news - www.globes-online.com - on October 5, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009